Pharmacokinetics of etoricoxib in patients with renal impairment (Q34544012)

2 August 2017

title

Pharmacokinetics of etoricoxib in patients with renal impairment (English)

1 reference

2 August 2017

1 reference

Nancy G B Agrawal

1

1 reference

2 August 2017

Catherine Z Matthews

2

1 reference

2 August 2017

Ralph S Mazenko

3

1 reference

2 August 2017

Walter F Kline

4

1 reference

2 August 2017

Eric J Woolf

5

1 reference

2 August 2017

Arturo G Porras

6

1 reference

2 August 2017

Leslie A Geer

7

1 reference

2 August 2017

Peggy H Wong

8

1 reference

2 August 2017

Meehung Cho

9

1 reference

2 August 2017

Josee Cote

10

1 reference

2 August 2017

Thomas C Marbury

11

1 reference

2 August 2017

Jack W Moncrief

12

1 reference

2 August 2017

Harry Alcorn

13

1 reference

2 August 2017

Suzanne Swan

14

1 reference

2 August 2017

Marshall R Sack

15

1 reference

2 August 2017

Richard A Robson

16

1 reference

2 August 2017

Kevin J Petty

17

1 reference

2 August 2017

Jules I Schwartz

18

1 reference

2 August 2017

Keith M Gottesdiener

19

1 reference

2 August 2017

publication date

1 January 2004

1 reference

The Journal of Clinical Pharmacology

2 August 2017

published in

1 reference

2 August 2017

volume

44

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

48-58

1 reference

Review article: COX-II inhibitors--a new generation of safer NSAIDs?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Renal effects of COX-2-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270003260338

21 January 2018

Identifiers

DOI

10.1177/0091270003260338

1 reference

2 August 2017

1 reference